In the last trading session, 1.08 million Olema Pharmaceuticals Inc (NASDAQ:OLMA) shares changed hands as the company’s beta touched 1.95. With the company’s per share price at $4.26 changed hands at -$0.36 or -7.79% during last session, the market valuation stood at $291.47M. OLMA’s last price was a discount, traded about -290.14% off its 52-week high of $16.62. The share price had its 52-week low at $2.86, which suggests the last value was 32.86% up since then. When we look at Olema Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 1.17 million shares, with the 3-month average coming to 937.75K.
Analysts gave the Olema Pharmaceuticals Inc (OLMA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended OLMA as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight.
Olema Pharmaceuticals Inc (NASDAQ:OLMA) trade information
Instantly OLMA was in red as seen at the end of in last trading. With action 1.67%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -61.48%, with the 5-day performance at 1.67% in the green. However, in the 30-day time frame, Olema Pharmaceuticals Inc (NASDAQ:OLMA) is -19.62% down. Looking at the short shares, we see there were 6.7 million shares sold at short interest cover period of 8.79 days.
The consensus price target for the stock as assigned by Wall Street analysts is 28.5, meaning bulls need an upside of 85.05% from its current market value. According to analyst projections, OLMA’s forecast low is 27 with 30 as the target high. To hit the forecast high, the stock’s price needs a -604.23% plunge from its current level, while the stock would need to soar -533.8% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -83.00%. The 2025 estimates are for Olema Pharmaceuticals Inc earnings to increase by 14.44%, but the outlook for the next 5-year period is at 6.25% per year.
OLMA Dividends
Olema Pharmaceuticals Inc is expected to release its next quarterly earnings report on 2025-May-13.
Olema Pharmaceuticals Inc (NASDAQ:OLMA)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 3.32% of Olema Pharmaceuticals Inc shares while 98.61% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 101.99%. There are 98.61% institutions holding the Olema Pharmaceuticals Inc stock share, with BVF INC/IL the top institutional holder. As of 2024-06-30, the company held 16.2322% of the shares, roughly 9.14 million OLMA shares worth $98.85 million.
PARADIGM BIOCAPITAL ADVISORS LP holds the second largest percentage of outstanding shares, with 14.0428% or 7.9 million shares worth $85.52 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . With 1.63 shares estimated at $6.95 million under it, the former controlled 2.38% of total outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held about 1.47% of the shares, roughly 1.01 shares worth around $4.29 million.
